Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Retrospective cohort study (Dec 1992–May 2017) found 30 cancer drug indications given accelerated approval by US FDA were not later reviewed by either European regulators or NICE and 12 drugs were not approved due to insufficient safety, clinical efficacy or cost-effectiveness.

JAMA Internal Medicine